HistoSonics is a technology company.
HistoSonics has raised $155.0M across 2 funding rounds.
HistoSonics has raised $155.0M in total across 2 funding rounds.
HistoSonics is a medical technology company that has developed the Edison® System, a non-invasive, robotically assisted platform delivering histotripsy—a proprietary sonic beam therapy that mechanically destroys targeted tissue at a sub-cellular level without incisions, needles, or thermal damage. The system primarily serves patients with liver tumors, offering a non-surgical alternative that reduces recovery time and complications. Since FDA clearance in 2023, the Edison System has been adopted at nearly 50 centers worldwide, treating over 1,000 patients, with plans to expand applications to other organs such as kidney, pancreas, and prostate. The company has experienced rapid growth, expanding from 40 employees in 2019 to over 200, and has sold over 100 systems globally[1][2][3][6].
Founded in 2009 by scientists at the University of Michigan, HistoSonics originated from decades of research in the Biomedical Engineering Department, particularly the discovery of histotripsy by Zhen Xu in 2001. The technology was initially supported by university programs like the Coulter Translational Research Partnership and Michigan’s innovation ecosystem. The company’s transformation accelerated under CEO Mike Blue and Senior Medical Advisor Dr. Fred Lee Jr. starting in 2017, who re-envisioned HistoSonics as a leader in scalable, non-thermal ultrasound therapy. Early traction included successful clinical trials and FDA clearance, culminating in a $2.25 billion acquisition by a consortium of top-tier investors in 2025, positioning the company for global expansion[2][5][6].
HistoSonics rides the trend of non-invasive, precision medicine and robotic-assisted therapies that aim to improve patient outcomes while reducing healthcare costs and recovery times. The timing is favorable due to increasing demand for alternatives to traditional surgery and radiation, alongside advances in imaging and robotics. The company’s technology leverages focused ultrasound, a growing modality in therapeutic ultrasound, positioning it at the forefront of a shift toward less invasive cancer treatments. Its success influences the broader ecosystem by validating histotripsy as a viable clinical tool and encouraging further innovation in sonic beam therapies[1][2][3][8].
Looking ahead, HistoSonics is poised to expand its clinical indications beyond liver tumors to other organs, potentially transforming treatment paradigms for multiple cancers. Continued innovation in robotic assistance and imaging will likely enhance precision and ease of use, driving broader adoption. The company’s strong investor backing and recent acquisition provide capital and strategic support to accelerate global market penetration. As non-invasive therapies gain traction, HistoSonics could become a key player shaping the future of oncology and surgical care, reinforcing its role as a pioneer in histotripsy technology[1][6].
HistoSonics has raised $155.0M in total across 2 funding rounds.
HistoSonics's investors include Johnson & Johnson Innovation, Sonder Capital.
HistoSonics has raised $155.0M across 2 funding rounds. Most recently, it raised $100.0M Series D in August 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Aug 1, 2024 | $100.0M Series D | Johnson & Johnson Innovation, Sonder Capital | |
| Apr 1, 2019 | $55.0M Series C | Sonder Capital |